ストックスクリーナーアプリを入手
3.36
0.30%
0.010
アフターアワーズ：
3.36
Cytomx Therapeutics Inc (CTMX) 最新ニュース
CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Point72’s 3.6% CytomX Therapeutics (CTMX) stake detailed in amended filing - Stock Titan
Kynam Capital reports 9.96% CytomX Therapeutics (CTMX) ownership in Schedule 13G/A - Stock Titan
CTMX Maintained by JP Morgan -- Price Target Lowered to $11.00 - GuruFocus
CytomX Therapeutics (NASDAQ:CTMX) Given New $11.00 Price Target at JPMorgan Chase & Co. - MarketBeat
CytomX Therapeutics Is Maintained at Overweight by JP Morgan - Moomoo
Bank of America Corp DE Has $47.95 Million Position in CytomX Therapeutics, Inc. $CTMX - MarketBeat
MSN Money - MSN
CytomX Therapeutics: Promising Varseta-M With Comfortable Runway (NASDAQ:CTMX) - Seeking Alpha
CTMX Maintained by Guggenheim -- Price Target Lowered to $14.00 - GuruFocus
Guggenheim cuts CytomX stock price target to $14 on model update - Investing.com South Africa
CytomX Therapeutics, Inc. $CTMX Shares Purchased by Dimensional Fund Advisors LP - MarketBeat
Q2 2026 CytomX Therapeutics Inc Earnings Call Transcript - GuruFocus
Q4 2025 CytomX Therapeutics Inc Earnings Call Transcript - GuruFocus
CytomX Therapeutics (CTMX) Stock Faces Revenue Collapse As Pipeline Hopes Carry The Story - Sahm
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of "Buy" by Brokerages - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) Announces Earnings Results - MarketBeat
CytomX Therapeutics, Inc. Stock 12‑Month Price Target Cut to $12.38, Implies 267% Upside - TradingView
State Street Corporation (CTMX) reports 5.4% beneficial stake in CytomX Therapeutics - Stock Titan
CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlight - GuruFocus
CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlights: Varetta M Advances Toward ... - Yahoo Finance
CytomX Therapeutics secures $37M from Regeneron amid Q2 revenue miss - scanx.trade
CytomX Q2 2026 Earnings: Revenue Falls as R&D Spending Rises - TradingKey
CytomX Therapeutics Q2 Earnings Call Highlights - marketbeat.com
CTMX Looks 1148.1% Overvalued on GF Value™ - GuruFocus
Earnings call transcript: CytomX misses Q2 2026 estimates as cash runway extends - Investing.com
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Is CytomX Therapeutics Inc (CTMX) Facing Financial Headwinds Aft - GuruFocus
CytomX Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update - The Manila Times
CytomX enrolls 113 patients; next colorectal cancer trial planned - Stock Titan
CytomX Therapeutics posts Q2 2026 results — $1.4M revenue, $25.2M operating expense, $330.3M cash - TradingView
CytomX Therapeutics 2Q 2026: Revenue $1.42M, EPS $(0.09) — 10-Q Summary - TradingView
CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlights: Varetta M Advances Toward ... By GuruFocus - Investing.com Canada
CytomX Therapeutics, Inc. (CTMX) awards 450,000 options and 100,000 RSUs to CLO - Stock Titan
CytomX Therapeutics, Inc. (CTMX) Chief Legal Officer files Form 3 insider report - Stock Titan
Bank of America (NYSE: BAC) discloses 7.0% ownership stake in CytomX (CTMX) - Stock Titan
CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer - The Manila Times
Press Release: CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer - Moomoo
InvestingPro’s Fair Value predicted 46% drop in CytomX stock By Investing.com - Investing.com
BlackRock, Inc. Adds to CytomX Therapeutics Inc (CTMX) Stake -- Shares Look 1007% Overvalued on GF Value - GuruFocus
Form 4 CytomX Therapeutics Inc For: 31 July By Investing.com - Investing.com Nigeria
CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026 - The Manila Times
CytomX Therapeutics Announces Date for Second Quarter 2026 Financial Results Conference Call - Quiver Quantitative
Ally Bridge Group NY LLC Makes New $4.23 Million Investment in CytomX Therapeutics, Inc. $CTMX - MarketBeat
Eversept Partners LP Has $14.99 Million Stock Holdings in CytomX Therapeutics, Inc. $CTMX - MarketBeat
BlackRock (CTMX holder) discloses 7.6% beneficial stake in CytomX Therapeutics - Stock Titan
CytomX appoints Charles Fuchs to board of directors By Investing.com - Investing.com South Africa
CytomX Therapeutics Inc (CTMX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors - The Manila Times
Charles Fuchs appointed to CytomX Board as Class II director - TradingView
More Than Three Decades in Oncology: Fuchs Joins CytomX Board - Stock Titan
Press Release: CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors - Moomoo
CytomX Therapeutics Inc (CTMX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CytomX Therapeutics Inc (CTMX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CTMX|CytomX Therapeutics Inc|Price:3.240|Chg%:-0.090 - TradingKey
TradingKey - TradingKey
Siren L.L.C. Purchases Shares of 3,457,711 CytomX Therapeutics, Inc. $CTMX - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) Raised to Strong-Buy at Zacks Research - MarketBeat
CTMX stock holds focus after CytomX strategy update - Ad-hoc-news.de
CytomX Therapeutics, Inc.Common Stock (NQ: CTMX - FinancialContent
CTMX Stock Garners Price Target Revisions After Colorectal Cancer Trial Data: Jefferies Sees As Much As 230% Upside - Stocktwits
CytomX Therapeutics (CTMX) Holds Near Support After Slight DipUpthrust Pattern - dars.gov.et
CytomX Therapeutics updates investors on its pipeline progress amid Nasdaq listing - Ad-hoc-news.de
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):